June 05, 2026

No, Keto Doesn't Cure Schizophrenia

The viral claim was wrong. The damage it did was real.

Conexiant

May 21, 2026

Gender-Diverse Youths Report More Psychotic Symptoms

Longitudinal cohort data linked bullying and persistently unsupportive state gender-identity policies with worsening psychotic-like experiences among gender-diverse youths.

Conexiant

May 19, 2026

Side Effects: When More Is Less

A gene variant that raises GLP-1 levels somehow makes GLP-1 drugs work worse. Plus: why your nose might still recover two years out, and what urine might eventually tell us about schizophrenia.

Conexiant

May 18, 2026

Could Digital Twins Forecast Forensic Risk?

Researchers outline a proposed three-level framework spanning patient monitoring, ward operations, and forensic system planning.

Conexiant

May 15, 2026

Urine Markers May Aid Psych Diagnosis

Genetically predicted urinary metabolite levels were associated with schizophrenia, bipolar disorder, attention-deficit/hyperactivity disorder, and anorexia nervosa in a Mendelian randomization analysis.

Conexiant

May 11, 2026

Stewardship Cuts Steroid Prescribing

Behaviorally informed peer comparison feedback was associated with a gradual decline in glucocorticoid prescribing

Conexiant

May 08, 2026

Premenstrual Disorders Linked to Broad Psychiatric Risk

Swedish study finds two-way associations between premenstrual disorders and psychiatric conditions, with strongest links involving depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, and personality disorders.

Conexiant

May 05, 2026

Low Follow-Up After Behavioral ED Care

Follow-up occurred after fewer than 15% of mental health ED visits and about 11% of substance use–related visits in Washington Medicaid claims.

Conexiant

April 30, 2026

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

Conexiant

April 29, 2026

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

Conexiant